cobimetinib
FDA Approves New MEK/BRAF Inhibitor Option for Melanoma Patients with BRAF V600E, V600K Mutations
Premium
Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.
Originally published Sept. 30.